|
COMPASS Pathways
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA). Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder (PTSD) New Drug Application (NDA), Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entere ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Pharmaceutical Industry
The pharmaceutical industry is a medical industry that discovers, develops, produces, and markets pharmaceutical goods such as medications and medical devices. Medications are then administered to (or self-administered by) patients for curing or preventing disease or for alleviating symptoms of illness or injury. Pharmaceutical companies may deal in generic drugs, branded drugs, or both, in different contexts. Generic materials are without the involvement of intellectual property, whereas branded materials are protected by chemical patents. The industry's various subdivisions include distinct areas, such as manufacturing biologics and total synthesis. The industry is subject to a variety of laws and regulations that govern the patenting, efficacy testing, safety evaluation, and marketing of these drugs. The global pharmaceutical market produced treatments worth a total of $1,228.45 billion in 2020. The sector showed a compound annual growth rate (CAGR) of 1.8% in 2021, ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
NASDAQ
The Nasdaq Stock Market (; National Association of Securities Dealers Automated Quotations) is an American stock exchange based in New York City. It is the most active stock trading venue in the U.S. by volume, and ranked second on the list of stock exchanges by market capitalization of shares traded, behind the New York Stock Exchange. The exchange platform is owned by Nasdaq, Inc. (which the exchange also lists; ticker symbol NDAQ), which also owns the Nasdaq Nordic stock market network and several U.S.-based stock and options exchanges. Although it trades stock of healthcare, financial, media, entertainment, retail, hospitality, and food businesses, it focuses more on technology stocks. The exchange is made up of both American and foreign firms, with China and Israel being the largest foreign sources. History 1972–2000 Nasdaq, Inc. was founded in 1971 by the National Association of Securities Dealers (NASD), which is now known as the Financial Industry Regulatory A ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Tactogen
Tactogen is a public benefit corporation and start-up pharmaceutical company based in Palo Alto, California that is developing novel MDMA-like entactogens and psychedelics as medicines. Its stated goal is to develop new MDMA-like drugs with improved effectiveness, tolerability, and safety, as well as gentleness and accessibility, for treatment of psychiatric disorders and other conditions. Tactogen was co-founded by neuroscientist Matthew J. Baggott and Luke Pustejovsky in 2020. Baggott is the chief executive officer (CEO) while Pustejovsky is the chief operating officer (COO). Drug candidates Tactogen has patented various novel entactogen-like compounds from different chemical families. These include benzofurans like 5-MAPB, 5-MBPB, and BK-5-MAPB, benzothiophenes like 5-MAPBT, α-alkyltryptamines like BK-NM-AMT and BK-5F-NM-AMT, indolizines like 2ZEDMA, 1ZP2MA, and Z2MAP1O, 2-aminoindanes like "BFAI", and non-racemic mixtures of enantiomers. It also has several dru ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Usona Institute
The Usona Institute is a 501(c)(3) non-profit medical research organization (MRO) which is developing psychedelic drugs for potential medical use. It was launched by scientist and entrepreneur Bill Linton, who is the founder of the biotechnology company Promega Corporation, and by physician Malynn Utzinger in 2014. The organization is developing psilocybin (4-HO-DMT) for treatment of depression. It started a phase 2 clinical trial of psilocybin for major depressive disorder in 2019. The same year, this candidate received Food and Drug Administration (FDA) "breakthrough therapy" designation. This clinical trial has since been completed and its psilocybin candidate is now in phase 3 clinical studies. In July 2024, it was said that the Usona Institute was leading the largest clinical trial of ongoing psilocybin treatment for depression, a phase 3 trial with 240participants treated with 5 or 25mg psilocybin or placebo. Other candidates of the institute include mebufotenin (5-MeO- ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cybin
Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines. The company's drug candidates include psilocybin (CYB001), CYB002 (discontinued), CYB003 ( deuterated psilocin), CYB004 (deuterated dimethyltryptamine (DMT)), CYB005 (deuterated phenethylamine derivative), and CYB006. Another drug that the company has developed is CYB210010 (2C-T-TFM). As of January 2025, CYB003 is in phase 3 clinical trial Clinical trials are prospective biomedical or behavioral research studies on human subject research, human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel v ...s. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 (psilocybin) to have reached this late stage of clinical development. In 2020, Cybin acquired psychedelic pharmaceutical company Adelia Therapeutics. See also * List of investigational hallucinogens and entact ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
